All In Biotech

Drug Trial Radar · NCT04426968

A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Jun 18, 2021

Primary completion

Nov 1, 2023

Study completion Nov 29, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined with Pegylated Interferon in Subjects with Chronic Hepatitis B

Conditions

  • Hepatitis B, Chronic

Interventions

  • Hepalatide 2.1mgDrug

    2.1 mg/day subcutaneously (s.c.) for 24 week

  • Hepalatide 4.2mgDrug

    4.2mg/day subcutaneously (s.c.) for 24 week

  • Hepalatide 6.3mgDrug

    6.3mg/day subcutaneously (s.c.) for 24 week

  • placebo 2.1mgDrug

    2.1 mg/day subcutaneously (s.c.) for 24 week

  • placebo 4.2mgDrug

    4.2 mg/day subcutaneously (s.c.) for 24 week

  • placebo 6.3mgDrug

    6.3 mg/day subcutaneously (s.c.) for 24 week

  • Pegylated InterferonDrug

    180 ug/week subcutaneously (s.c.) for 28 week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. virological responseTime frame: 24weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Jilin Hepatobiliary Disease Hospital

    Changchun, China

  • The first hospital of Jilin University

    Changchun, China

  • Chizhou People's Hospital

    Chizhou, China

  • The First Hospital Affiliated to the Army Medical University

    Chongqing, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The Second Hospital of Nanjing

    Nanjing, China

  • Qingyuan People's Hospital

    Qingyuan, China

  • Shanghai Tongren Hospital

    Shanghai, China

  • The Sixth People's Hospital of Shenyang

    Shenyang, China

  • Henan Provincial People's Hospital

    Zhengzhou, China

  • Henan Provincial Infectious Disease Hospital

    Zhenzhou, China

  • The fifth medical center of PLA

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.